SCHEMBL4538386

SCHEMBL4538386

COc1cc(C2C(C(=N)NO)=C(N)Oc3c2ccc2ccccc32)cc(Br)c1OC

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MYB P10242 16/20 0.59
TUBB4A P04350 2/20 0.49
TUBB P07437 2/20 0.49
TUBA3C P0DPH7 2/20 0.49
TUBA1B P68363 2/20 0.49
TUBA4A P68366 2/20 0.49
TUBB4B P68371 2/20 0.49
TUBB3 Q13509 2/20 0.49
TUBB2A Q13885 2/20 0.49
TUBB8 Q3ZCM7 2/20 0.49
TUBA3E Q6PEY2 2/20 0.49
TUBA1A Q71U36 2/20 0.49
TUBA1C Q9BQE3 2/20 0.49
TUBB6 Q9BUF5 2/20 0.49
TUBB2B Q9BVA1 2/20 0.49
TUBB1 Q9H4B7 2/20 0.49
ACHE P22303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4538391 0.86 MYB (0.59) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6014324 0.86 MYB (0.59) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5044919 0.84 MYB (0.63) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4331540 0.82 MYB (0.87) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL15370260 0.80 MYB (0.54) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL20368810 0.77 MYB (0.55) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4561271 0.76 MYB (0.58) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4537494 0.76 MYB (0.55) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5044967 0.76 MYB (0.59) MYBACHE
SCHEMBL4541509 0.75 MYB (0.57) MYBTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2638025-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2020-02-05 EP disclosed
US-20180334442-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS Ruprecht-Karls-Universität Heidelberg (DE) 2018-11-22 US disclosed
US-10065939-B2 Chromene derivatives and their analogs as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2018-09-04 US disclosed
EP-2638026-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2018-07-11 EP disclosed
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-12-08 US disclosed
US-9371333-B2 Chromene derivatives and their analoga as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-06-21 US disclosed
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-14 US disclosed
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-07 US disclosed
EP-2638026-A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS Deutsches Krebsforschungszentrum (DKFZ) (DE) 2013-09-18 EP disclosed
EP-2638025-A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS Deutsches Krebsforschungszentrum (DKFZ) (DE) 2013-09-18 EP disclosed
WO-2012062905-A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) 2012-05-18 WO disclosed
WO-2012062901-A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A MYB 142/4885TUBB4A 2905/4885TUBB 3789/4885
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A MYB 152/4885TUBB4A 3213/4885TUBB 3786/4885
US-10065939-B2 Chromene derivatives and their analogs as Wnt pathway antagonists WNT3, WNT1, WNT3A MYB 152/4885TUBB4A 3213/4885TUBB 3786/4885
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A MYB 172/4885TUBB4A 3809/4885TUBB 4669/4885
US-20180334442-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A MYB 152/4885TUBB4A 3213/4885TUBB 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.